

CELSION CORP  
Form 8-K  
July 28, 2003

---

OMB APPROVAL

---

OMB Number: 3235-0060

---

Expires: October 31, 2005

---

Estimated average burden  
Hours per response: 15.00

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

---

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 OR 15(D) of the  
Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): July 8, 2003

---

**Celsion Corporation**

---

(Exact name of Registrant as Specified in Charter)

**Delaware**

---

(State of Other Jurisdiction  
of Incorporation)

**000-14242**

---

(Commission  
File Number)

**52-1256615**

---

(IRS Employer Identification No.)

**10220-I Old Columbia Road, Columbia, Maryland**

---

(Address of principal executive office)

**21046-1705**

---

(Zip Code)

Registrant's telephone number, including area code: (410) 290-5390

---

(Former Name or Former Address, if Changed Since Last Report)

---

**Item 5. Other Events**

On July 23, 2003, Celsion Corporation (the Company) completed a private placement of approximately 9.5 million shares of its common stock, par value \$0.01 per share and warrants to purchase approximately 2.85 million shares of common stock (representing 30% warrant coverage) exercisable at \$1.20 per share. The placement was priced at \$0.77 per share and associated warrant and yielded gross proceeds of approximately \$7.3 million. The proceeds from the private placement will, after the payment of transaction costs and together with proceeds received from recent exercises of outstanding common stock purchase warrants, be used to complete the commercial development and the regulatory approval process for the Company's Microfocus® BPH 800 Microwave Urethroplasty System, continue clinical trials of the Company's breast and prostate cancer treatment systems, further research for the Company's heat-activated liposomes and Cancer Repair Inhibitor (CRI) technology and for working capital and general corporate purposes through the end of the Company's 2004 fiscal year. The Company also issued warrants to purchase approximately 1.1 million shares of common stock, exercisable at \$0.77 per share, as part of the compensation to its placement agent.

On July 8, 2003, the Company issued a press release regarding the anticipated receipt of \$4.5 million in gross proceeds that day upon the first closing of the private placement and the receipt, between May 28, 2003 and July 8, 2003, of approximately \$5.1 million in proceeds from warrant exercises. A copy of that press release is attached as Exhibit 99.1 to this Report on Form 8-K.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

CELSION CORPORATION

Dated: July 25, 2003

By: /s/ Anthony P. Deasey

---

Executive Vice President-Finance and  
Administration and Chief Financial Officer

-3-

---

**EXHIBIT INDEX**

<b>Exhibit</b>	<b>Description</b>
99.1	Registrant's Press Release dated July 8, 2003